Chinese Journal of Tissue Engineering Research ›› 2026, Vol. 30 ›› Issue (34): 9041-9047.doi: 10.12307/2026.819

Previous Articles     Next Articles

Key role of m6A methylation in sarcopenia

Li Jiatong1, Liang Songlin1, Liu Runjia2, Li Nianhu1, 3   

  1. 1Shandong University of Traditional Chinese Medicine, Jinan 250014, Shandong Province, China; 2Guang’anmen Hospital, Chinese Academy of Chinese Medical Sciences, Beijing 100032, China; 3Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan 250014, Shandong Province, China

  • Received:2025-08-01 Revised:2025-12-08 Online:2026-12-08 Published:2026-04-15
  • Contact: Li Nianhu, MD, Professor, Doctoral supervisor, Chief physician, Shandong University of Traditional Chinese Medicine, Jinan 250014, Shandong Province, China; Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan 250014, Shandong Province, China
  • About author:Li Jiatong, Shandong University of Traditional Chinese Medicine, Jinan 250014, Shandong Province, China
  • Supported by:
    Shandong Provincial Natural Science Foundation Project, No. ZR2023MH063 (to LNH); Xu Zhanwang National Famous Veteran Traditional Chinese Medicine Experts Inheritance Studio Construction Project, No. [2022]75 (to LNH) 

Abstract: BACKGROUND: The role of epigenetic regulatory mechanisms, especially N6 methyladenine (m6A) RNA modification, in muscle cell proliferation, differentiation, and disease development is increasingly being studied. However, the multidimensional mechanism of m6A methylation in sarcopenia still needs to be systematically integrated.
OBJECTIVE: To explore the key role of m6A methylation in the occurrence and development of sarcopenia, and to review the latest research progress on the involvement of m6A related regulatory factors in the pathological process of sarcopenia. 
METHODS: Using “m6A methylation, N6 methyladenine, sarcopenia, muscle atrophy, muscle regeneration, muscle, skeletal muscle” as Chinese keywords, and “m6A RNA methylation, sarcopenia, skeletal muscle, muscle mass loss”, as English keywords, CNKI and PubMed were searched to screen high-quality literature in recent years, and the mechanism of action and related signaling pathways of m6A methylation in sarcopenia were summarized. 
RESULTS AND CONCLUSION: m6A methylation participated in the pathological process of sarcopenia through a dynamically reversible regulatory network (N6-adenosine-methyltransferase 70 kDa subunit (METTL3)/METTL14, fat mass and obesity associated protein FTO/ AlkB homolog 5, RNA demethylase ALKBH5, YTH N6-methyladenosine RNA binding protein C1 (YTHDC1)/YTHDF2). m6A methylation affected the proliferation and differentiation of skeletal muscle cells by regulating mechanisms such as satellite cells, ubiquitin proteasome system, and non-coding RNA. Most studies are based on cell models or animal experiments, with limited research on clinical sample validation and translational applications. The feasibility of m6A-related factors as diagnostic markers or therapeutic targets for sarcopenia needs further validation.  


Key words: m6A methylation, sarcopenia, skeletal muscle, satellite cells, protein metabolism, non-coding RNA

CLC Number: